Data di Pubblicazione:
2006
Citazione:
Cutaneous effects of anti-EGFR cetuximab : dermatological management / S. Motta, L.L. Mancini, M.R. Monti. - In: SUPPORTIVE AND PALLIATIVE CANCER CARE. - ISSN 1824-601X. - 2:3(2006), pp. 105-108.
Abstract:
Target therapy, using drugs inhibiting specific cell surface receptors, represents a new oncologic approach for several tumour histotypes. Cetuximab is a monoclonal antibody that binds the epidermal growth factor receptor (EGFR) and inhibits cycle, proliferation, differentiation, and survival of cancer cells. The exact role of the EGFR on the epidermic cells has not been accurately elucidated. Systemic use of cetuximab for blocking EGFR provides new interesting information about the physiological role of this receptor on keratinocytes. Cutaneous reactions during cetuximab treatment are very peculiar and require specific dermatological treatments.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Anti-epidermal growth factor receptor (EGFR) ; cetuximab ; cutaneous side effetcs ; topical therapy
Elenco autori:
S. Motta, L.L. Mancini, M.R. Monti
Link alla scheda completa: